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Abstract Magnesium is essential to the proper function-
ing of numerous cellular processes. Magnesium ion
(Mg2+) deficits, as reflected in hypomagnesemia, can
cause neuromuscular irritability, seizures and cardiac ar-
rhythmias. With normal Mg2+ intake, homeostasis is
maintained primarily through the regulated reabsorption
of Mg2+ by the thick ascending limb of Henle’s loop
and distal convoluted tubule of the kidney. Inadequate
reabsorption results in renal Mg2+ wasting, as evidenced
by an inappropriately high fractional Mg2+ excretion.
Familial renal Mg2+ wasting is suggestive of a genetic
cause, and subsequent studies in these hypomagnesemic
families have revealed over a dozen genes directly or in-
directly involved in Mg2+ transport. Those can be classi-
fied into four groups: hypercalciuric hypomagnesemias
(encompassing mutations in CLDN16, CLDN19, CASR,
CLCNKB), Gitelman-like hypomagnesemias (CLCNKB,
SLC12A3, BSND, KCNJ10, FYXD2, HNF1B, PCBD1),
mitochondrial hypomagnesemias (SARS2 , MT-TI ,
Kearns–Sayre syndrome) and other hypomagnesemias
(TRPM6, CNMM2, EGF, EGFR, KCNA1, FAM111A).
Although identification of these genes has not yet
changed treatment, which remains Mg2+ supplementation,
it has contributed enormously to our understanding of
Mg2+ transport and renal function. In this review, we dis-
cuss general mechanisms and symptoms of genetic causes
of hypomagnesemia as well as the specific molecular
mechanisms and clinical phenotypes associated with each
syndrome.
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Introduction
Magnesium is a vital element for the human body and is
involved in numerous biological processes. It is the
second-most abundant intracellular cation (Mg2+) in the
human body and is crucial for the function of over 600
enzymes and regulation of the activity of several ion
channels, as well as for stabilization of negatively charged
molecules such ATP, ADP, RNA and DNA (reviewed in
[1]). In order to constantly suffice the body’s requirements
for this ion, there is a significant storage capacity for
Mg2+: an adult human body usually contains about 24 g
of Mg2+ at any one time [1]. Blood serum only contains a
fraction of this, with normal serum Mg2+ concentrations
[Mg2+] ranging from 0.70 to 1.1 mM, which translates to
about 60 mg in total. Even though only two-thirds of this
is biologically active (the ionized fraction), total serum
Mg2+ concentrations are still used in daily practice as a
measurement of the total Mg2+ status of a patient.
Accordingly, hypomagnesemia is defined as a serum
[Mg2+] < 0.70 mM (<1.7 mg/dL) and hypermagnesemia
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as a serum [Mg2+] > 1.1 mM (>2.5 mg/dL). A shortage of
Mg2+ can have direct consequences, some well-
established, others less clear, but it is also associated with
several other diseases. Direct consequences or symptoms
that might arise from hypomagnesemia are variable in
severity and may correlate to the extent and duration of
the Mg2+ shortage, ranging from leg cramps and tiredness
to seizures, coma and eventually death (Table 1). In addi-
tion, (severe) hypomagnesemia may have further conse-
quences during pregnancy, as suggested by findings that a
Mg2+-deficient diet in pregnant mice was able to induce
fetal malformations [2]. Conversely, supplementation with
magnesium sulfate (MgSO4) during pregnancy is a treat-
ment for pre-eclampsia [3], suggesting a role for a relative
shortage of Mg2+ in this disease too. Lastly, some dis-
eases, such as Parkinson’s disease and diabetes, have
merely been associated with low serum Mg2+ concentra-
tions (reviewed in [1]). It is not yet clear, however, wheth-
er hypomagnesemia is the cause, a consequence or simply
an epiphenomenon in these diseases.
Most of our current knowledge about Mg2+ homeostasis
has been obtained by studying the molecular mechanisms
through which genetic mutations cause hypomagnesemia.
The aim of this review is to provide an update of the currently
known genetic defects in Mg2+ homeostasis from a clinical
point of view, discussing firmly established knowledge as well
as several recently discovered or neglected hereditary
hypomagnesemic syndromes.
Maintaining Mg2+ homeostasis
The daily dietaryMg2+ intake recommended by theU.S. Institute
of Medicine is dependent on age (Table 2). Approximately
30–50 % of the ingested Mg2+ will be absorbed by the intestine,
although this has been reported to increase to 80 % in cases of
Mg2+ deficiency. The bulk of the dietary Mg2+ is initially
absorbed in the jejunum and ileum via paracellular pathways.
The remainder can be absorbed by the colonic epithelium, enter-
ing the cells via transient receptor potential melastatin type 6
(TRPM6), an essential ion channel and serine/threonine-protein
kinase, and probably exiting the cells at the basolateral side by
making use of the sodium (Na+) gradient and the Na+–Mg2+
exchanger cyclinM4 (CNNM4). Mg2+ subsequently enters the
bloodstream to be delivered to cells, excreted by the kidneys or
stored in bones. The large skeletal stores (50–60 % of total body
Mg2+) are in part responsible for keeping the serum Mg2+
concentrations constant (reviewed in [1]).
An even more important role in the regulation of Mg2+
homeostasis has been given to the kidney. After glomerular
ultrafiltration, a mere 10–25 % of Mg2+ is reabsorbed by the
proximal convoluted tubule (PCT) through paracellular path-
ways. Next, a further 50–70 % of the filtered Mg2+ is
reabsorbed via paracellular pathways in the thick ascending
limb of Henle’s loop (TAL), where claudins play a key role in
regulating paracellular calcium (Ca2+) and Mg2+ transport [4]
(see Fig. 1). Lastly, fine-tuning of the total Mg2+ reabsorption
takes place in the distal convoluted tubule (DCT), which ab-
sorbs the final 5–10 % via transcellular pathways [5].
Essential for this last step is the apical Mg2+ channel
TRPM6, the same channel that is responsible for Mg2+ trans-
port in the large intestine (reviewed in [1]). The activity of this
channel and its expression in the membrane are positively
regulated through epidermal growth factor (EGF)-activated
pathways [6] (see Fig. 1). Finally, also insulin, estrogen, ex-
tracellular pH, ATP, oxidative stress and Mg2+ itself are all
found to be able to influence the magnitude of Mg2+ transport
in the DCT [1]. Towards the end of this last segment, 95–99%
Table 1 Direct consequences of hypomagnesemia
Direct consequences of hypomagnesemiaa
Chvostek and Trousseau’s signs
Tiredness
Generalized weakness
Tremor
Paresthesias and palpitations
Hypokalemia
Hypoparathyroidism resulting in hypocalcemia
Chondrocalcinosis
Failure to thrive (in children)
Spasticity and tetany
Seizures
Electrocardiography changes, including prolonged QT interval
(especially with concomitant hypokalemia)
Cardiac arrhythmias (especially with concomitant hypokalemia)
Basal ganglia calcifications
Coma
Intellectual disability
Death
a Consequences of hypomagnesemia are presented from top to bottom of
table in order of increasing severity
Table 2 Recommended dietary allowance of magnesium (Mg2+)
Age (years) RDA for males
(mg Mg2+/day)
RDA for females
(mg Mg2+/day)a
0-1 NA NA
1–3 80 80
4–8 130 130
9–13 240 240
14–18 410 360
19–30 400 310
>31 420 320
RDA, Recommended dietary allowance; NA, information not available
a For women during pregnancy the RDA is slightly higher
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of filtered Mg2+ has been reabsorbed in total, and no further
reabsorption takes place beyond this point [7].
Disturbances of Mg2+ homeostasis
Hypomagnesemia is defined as total serum Mg2+ concentra-
tions below 0.70 mM (<1.7 mg/dL), while hypermagnesemia
is reserved for concentrations above 1.1 mM (>2.7 mg/dL).
Symptomatic hypermagnesemia is rare and mostly induced
by excessive use of drugs which contain high amounts of
Mg2+, including laxat ives and Epsom sal ts [1] .
Hypomagnesemia on the other hand is more frequent [8–10]
and can have several distinct causes. First among these is a
prolonged general loss of electrolytes, such as during periods
of vomiting, diarrhea or malabsorption [11]. Secondly, several
genetic disorders are accompanied by hypomagnesemia (see
Table 4). Thirdly, albeit rare in the pediatric population, use of
alcohol and certain drugs (Table 3; reviewed in [1]) should be
considered. Lastly, contemporary food intake is relatively poor
in Mg2+ [12] and may therefore contribute to the development
of hypomagnesemia.
Diagnosing renal Mg2+ wasting
The most important clinical diagnostic tool for differentiat-
ing hypomagnesemia of renal origin from intestinal hypo-
magnesemia is determination of the fractional excretion of
magnesium (FEMg) [13], which can be calculated with the
TRPM6
Kv1.1
NCC
NKCC2
Barttin
ClC-Kb
ADP ATPMg2+
Cl-
Na+
K+
FXYD2
Na-K-ATPase
Kir4.1
HNF1B
PCBD1
ROMK
Claudin16
Claudin19
Claudin14
EGF EGFR
Rac1 PI3KAkt
CaSR
Cl-
Na+
K+
Cl-
Na+
K+
K+
Cl-
Na+
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Mg2+
Ca2+
ClC-Kb
Na-K-ATPase
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CNNM2
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Fig. 1 Reabsorption of the
magnesium cation (Mg2+) in the
thick ascending limb of Henle’s
loop (TAL) and distal convoluted
tubule (DCT). The relevant
molecular transport mechanisms
of the TAL and DCT are shown.
Note that Mg2+ is transported via
paracellular pathways into the
TAL and via transcellular
pathways into the DCT. A more
detailed explanation of the
molecular transport mechanisms
can be found in the text. Black
text indicates proteins that are
mutated in genetic disorders of
Mg2+ homeostasis. Grey text
indicates other proteins
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following formula: {([Mg2+]urine × [creatinine]plasma)/ (0.7
[Mg2+]plasma × [creatinine]urine)}×100 %. The factor of 0.7
is included to adjust the total plasma Mg2+ concentration to
the freely filtered fraction. A FEMg of >4 % in a
hypomagnesemic patient is consistent with renal Mg2+
wasting, while a patient with a FEMg of<2 % will likely
have an extra-renal origin of their hypomagnesemia [13].
However, a FEMg<4 % does not rule out renal Mg2+
wasting. First, a low glomerular filtration rate may result
in a lower filtered load of Mg2+. If the absorptive capacity
of the kidney for Mg2+ is sufficient to cope with this lower
load, the result may be a normal or even low FEMg. By the
same mechanism, severe (renal) hypomagnesemia may re-
sult in a lower filtered load of Mg2+ and thus a normal or
low FEMg. To account for these confounding factors, the
serum Mg2+ levels of hypomagnesemic patients should be
increased by means of intravenous Mg2+ supplementation
before the FEMg is measured [14].
Hereditary hypomagnesemias
The genetic causes of hypomagnesemia are heterogeneous
and comprise both recessive and dominant disorders
(Table 4). The localization of the responsible genes is firmly
established: all known genes encode proteins expressed in the
DCTand/or TAL (Fig. 1). Nevertheless, the exact mechanisms
at the molecular level remain to be elucidated for many of
these diseases.We therefore propose four categories of genetic
causes of hypomagnesemia based on similar manifestation,
electrolyte abnormalities and localization. The resulting clas-
ses presumably also reflect a common pathophysiological
mechanism for each group.
Hypercalciuric hypomagnesemias
The hypercalciuric hypomagnesemias are a class of hypomag-
nesemias in which the ability of the TAL to reabsorb divalent
cations is affected. Ca2+ andMg2+ reabsorption takes place via
paracellular pathways in the TAL and is therefore strongly
dependent on the lumen positive transepithelial potential dif-
ference. Consequently, disruption of this voltage difference or
of the integrity of this paracellular pathway will impair both
Ca2+ and Mg2+ transport (reviewed in [4]). In two of the four
types of Bartter syndrome, the lumen positive transepithelial
voltage difference is decreased, while mutations in the CASR,
CLDN16 and CLDN19 genes are proposed to interfere with
the integrity of the pathway as well as the voltage difference
[4]. Compensatory mechanisms in the DCT and other seg-
ments, however, may be able to avert hypomagnesemia (in
Bartter syndrome type 1 and 2) or hypercalciuria (in Bartter
syndrome type 4) [15]. This only leaves Bartter syndrome
type 3, which impairs both TAL and DCT function (reviewed
in [15]), as meeting the criterion for this group. Clinically,
genetic disorders in this group can result in nephrocalcinosis
or in chronic kidney disease (CKD), although the incidence
and speed of progression differs from one to the other [4, 15].
CLDN16 and CLDN19 (familial hypomagnesemia
with hypocalcemia and nephrocalcinosis)
Recessive mutations in CLDN16 (encoding claudin-16) and
CLDN19 (encoding claudin-19) are the most frequent cause of
hypercalciuric hypomagnesemia [16, 17]. These claudin mu-
tations disrupt the pore selectivity of the tight junction,
impairing paracellular Ca2+ and Mg2+ reabsorption in the
TAL (reviewed in [18]). Consequently, patients suffer from
hypomagnesemia and its associated symptoms, childhood
nephrocalcinosis possibly due to the hypercalciuria and poly-
uria with polydipsia due to additional sodium (Na+) and vol-
ume loss [19]. Patients with CLDN19 mutations will also ex-
hibit ocular anomalies [17]. The renal prognosis for both types
is poor, with progressive CKD requiring renal replacement
therapy typically in the second or third decade of life [20].
The cause of the CKD is unclear, although nephrocalcinosis
may be a contributory factor.
CASR gain-of-function (autosomal dominant
hypocalcemia with hypercalciuria)
Gain-of-function mutations in the gene encoding the calcium
sensing receptor CaSR (CASR) are associated with hypercal-
ciuric hypocalcemia and occasionally with hypomagnesemia
[21, 22]. The two large exofacial lobes of the CaSR act as a
peritubular Ca2+ andMg2+ sensor in the TAL and other tissues
(reviewed in [23]). Gain-of-function mutations, analogous to
higher Ca2+ concentrations, cause the CaSR to suppress salt
reabsorption in the TAL and interfere with the claudin-
mediated pore selectivity in the tight junctions (reviewed in
[23]). Hypercalciuric hypocalcemia with relative hypopara-
thyroidism is the most important symptom, which, especially
when Bmist rea ted^ with vi tamin D, can lead to
nephrocalcinosis in certain cases (reviewed in [24]).
Table 3 Drugs associated with hypomagnesemia
Drugs associated with hypomagnesemia
Diuretics (furosemide, thiazide)
Epidermal growth factor receptor inhibitors (cetuximab)
Proton pump inhibitors (all, such as omeprazole)
Calcineurin inhibitors (cyclosporin A, tacrolimus)
Platinum derivatives (cisplatin, carboplatin)
Antimicrobials (aminoglycosides, pentimidine, rapamycin, amphotericin
B, foscarnet)
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Moreover, in patients with more severe gain-of-function of
CASR, significant wasting of Mg2+, Na+, potassium (K+)
and water can also occur [22]. This has led to the alternative
name of Bartter syndrome type V in patients with this severe
type of presentation [22].
CLCNKB (Bartter syndrome type III)
Homozygous or compound heterozygous mutations in
CLCNKB, which encodes the chloride ion (Cl−) channel
ClC-Kb, cause Bartter syndrome type III. ClC-Kb is
expressed basolaterally in the TAL and DCT, providing
a pathway for (Cl−) to exit the cell. Mutations in the
channel therefore interfere with regulation of intracellular
chloride levels and the function of NCC (thiazide-
sensitive NaCl cotransporter) and NKCC (Na+-K+-Cl−
cotransporter) (reviewed in [15, 25] and [26]). Patients
with mutations in CLCNKB often present during the first
years of life, suffering from a Bartter-like phenotype, in-
cluding hypercalciuria and loss of Na+, K+ and water.
When they grow older, however, a shift to a more
Gitelman-like phenotype can be observed, with marked
hypocalciuria and hypomagnesemia in addition to the loss
of Na+, K+ and water [25, 27]. The CLCNKB gene is thus
listed under the hypercalciuric as well as under the
Gitelman-like hypomagnesemias.
Gitelman-like hypomagnesemias
The genes from the second group of hypomagnesemias
listed in Table 4, the Gitelman-like hypomagnesemias,
all encode proteins that are involved in the transport of
Na+, K+ and/or Cl− in the DCT. Adequate transcellular
Mg2+ reabsorption in the DCT is dependent on the apical
membrane potential, which is lumen positive when com-
pared to the cytoplasm (reviewed in [28]). Therefore,
Mg2+ reabsorption also depends on the intactness of other
ion transport processes in the DCT. Alternatively, it has
been proposed that atrophy of the DCT segment is respon-
sible for all symptoms [29], although thiazide diuretics do
not cause atrophy of the DCT [30]. Regardless of the
mechanism underlying the DCT dysfunction, diseases
from this group of hypomagnesemias all lead to increased
calcium reabsorption along different nephron segments,
proximal as well as distal (reviewed in [29]). This obvi-
ously results in hypocalciuria. In addition, the DCT dys-
function leads to fluid loss and a tendency to lower blood
pressures despite an activated renin–angiotensin–aldoste-
rone system (due to compensation mechanisms) (reviewed
in [31]). Lastly, the relatively increased levels of aldoste-
rone force the collecting duct to secrete potassium in ex-
change for sodium, leading to hypokalemia, which, in
turn, leads to alkalosis. In addition, the combination of
hypomagnesemia with hypokalemia observed in this
group can give rise to a prolonged QT interval and cardiac
arrhythmias [32–34], justifying avoidance of drugs
prolonging the QT interval [32].
SLC12A3 (Gitelman syndrome)
With an estimated prevalence of 1:40 000 [31], Gitelman syn-
drome is the most frequent genetic cause of hypomagnesemia.
It is caused by recessive mutations in SLC12A3, the gene
encoding the Na+-Cl−-cotransporter (NCC) that is expressed
on the apical membrane of the DCT [35] (reviewed in [31]).
Symptoms are generally absent in the first years of life and
only towards the end of the first decade do patients start to
report symptoms [36]. Affected individuals can suffer from a
range of hypomagnesemia-related symptoms, such as cramps,
paresthesias or even cardiac arrest [32, 37]. In addition, they
can suffer from the salt and water wasting that is apparent in
most Gitelman-like hypomagnesemias, resulting in polyuria,
salt craving and thirst [37]. The mechanism by which
Gitelman syndrome causes hypomagnesemia is still not fully
understood. One explanation can be found in the atrophy of
the DCT that has been observed in a mouse model of
Gitelman syndrome [29]. Additionally, a reduced apical mem-
brane potential and a reduction in TRPM6 activation or mo-
bilization could play a role. It may be speculated that the
reduced apical membrane potential is caused by increased
NHE2 (Na+/H+ exchanger)-mediated Na+ reabsorption in the
DCT as a means to compensate for the NCC dysfunction.
BSND (Bartter syndrome type IV)
Barttin, encoded by the BSND gene, is expressed in the as-
cending thin limb, TAL, DCTand inner ear as a subunit of the
ClC-Kb and ClC-Ka Cl− channels (reviewed in [15, 26]).
Consequently, patients with recessive mutations in BSND or
digenic mutations affecting both ClC-Kb and ClC-Ka will
suffer from profound salt wasting in these three tubule seg-
ments as well as sensorineural deafness. In addition to com-
plete deafness, Bartter syndrome type IV can be distinguished
from the other types of Bartter syndrome by the initial lack of
hypercalciuria. In addition, a significant number of patients
will develop CKD (reviewed in [15, 26]). Most important
for treatment is the adequate supplementation of fluids and
sodium directly after birth, much alike all other types of salt-
losing tubulopathies with antenatal presentation [38]. Long-
lasting treatment with indomethacin can be considered to pre-
vent failure to thrive and decrease renal salt and water wasting,
but it should be realized that this treatment will be less effec-
tive than in patients with Bartter types I and II [39] and that
this drug can cause renal side effects.
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KCNJ10 (epilepsy, ataxia, sensorineural deafness
and tubulopathy syndrome)
This syndrome, characterized by epilepsy, ataxia, sensorineu-
ral deafness and tubulopathy (referred to as EAST syndrome),
is a rare recessive genetic disease affecting the K+ channel
Kir4.1 encoded by KCNJ10 [40]. This protein is expressed
in several tissues, including the central nervous system, inner
ear and basolateral side of DCT cells and possibly also TAL
cells (reviewed in [41, 42]). In the kidney it forms a basolateral
K+ channel that conducts outward K+ currents, thus recycling
the K+ imported by the Na+-K+-ATPase. To aid in diagnosis,
magnetic resonance imaging of the brain might show subtle
changes, especially in the dentate nuclei of the cerebellum
[41]. Patients show often pronounced ataxia and obligate sen-
sorineural deafness. Lastly, although intellectual abilities seem
to lag behind [43], it is difficult to assess the intelligence of
these patients due to deafness and ataxia impairing both verbal
and written communication [44].
FXYD2 (isolated dominant hypomagnesemia)
Only three families, all Belgian or Dutch, putatively descen-
dants from a common founder [45], have been reported to
carry the hypomagnesemia-causing FXYD2 mutation. The
FXYD2 gene encodes the γ-subunit of the Na+-K+-ATPase
[46]. The specific dominant mutation causes misrouting of
this γ-subunit, thereby preventing the splice variant
FXYD2b from assembling with the α- and β-subunit of the
Na+-K+-ATPase [46]. Virtually all patients suffer frommuscle
cramps; additionally, several other hypomagnesemia-related
symptoms can occur [45].
HNF1B (autosomal dominant tubulointerstitial kidney
disease)
Heterozygous mutations in the HNF1B gene are associated
with a multi-system disorder and considered to be the most
common genetic cause of congenital anomalies of the kidney
and urinary tract (CAKUT) (reviewed in [47, 48]). The
HNF1B gene is situated in a region susceptible for genomic
rearrangements, resulting in a high frequency of large dele-
tions and de novo gene defects [47]. Mutations in this gene
can be detrimental to normal development and function of the
kidney, pancreas and genital tract [47], thus giving rise to a
highly variable set of symptoms originating from these or-
gans, including CAKUT and maturity onset diabetes in the
young (MODY).
Hypomagnesemia is also one of these symptoms, occurring
in up to 50 % of affected children [49] and sometimes being
the first clinical manifestation [50]. Hypomagnesemia be-
comes more pronounced with increasing age of the patient
and can be missed in affected young children. As a result,
HNF1B mutations are the most common cause of genetic
hypomagnesemia for pediatric nephrologists. The current
view is that HNF1B dysfunction leads to inadequate transcrip-
tion of the FXYD2 splice-isoformFXYD2a, which encodes the
γa-subunit of the Na+-K+-ATPase [51]. The diagnosis is com-
plicated by the large variability in presentation and the lack of
a clear genotype–phenotype relationship [47]. If a patient is
considered to suffer from HNF1B-ADTKD, the diagnosis
should only be rejected if point-mutations as well as deletions
and insertions in HNF1B have been properly excluded.
PCBD1 (renal cyst and diabetes-like)
Recessive mutations in PCBD1 had long been identified to be
responsible for transient neonatal hyperphenylalaninemia and
primapterinuria (HPABH4D) [52], but no other symptoms of
this genetic defect had been reported until recently. Re-
evaluation of earlier identified patients with this syndrome
revealed that hypomagnesemia and MODY5-like diabetes
are later manifestations of PCBD1 mutations [53, 54]. This
finding also has implications for the importance of looking for
alternative genetic diagnoses (including PCBD1 mutations) if
screening for mutations of PAH (phenylalanine hydroxylase)
is negative after a positive result for the Guthrie test.
The neonatal phenotype can be explained by the failure of
PCBD1 to fulfil its role as an enzyme in the metabolism of
aromatic acids. The complications appearing later in life are
explained by the additional role of PCBD1 as a dimerization
factor for HNF1A andHNF1B, regulating their transcriptional
activity (reviewed in [53]). This in turn would influence
FXYD2 transcription, causing hypomagnesemia. It should be
noted, however, that the CAKUT phenotype often observed in
HNF1B patients is not seen in PCBD1-disease due to a dif-
ferent expression pattern of these two proteins. Lastly, hypo-
kalemia and hypocalciuria have not been reported in these
patients. Still, it is placed here with the Gitelman-like hypo-
magnesemias based on the pathophysiological mechanism.
Mitochondrial hypomagnesemias
The mitochondrial hypomagnesemias, of which the patho-
physiological mechanism is still unexplained, have a highly
variable presentation. Their phenotype depends both on the
nature of the mutation and the fraction of mitochondria affect-
ed in each tissue (reviewed in [55]). Some of the mitochon-
drial hypomagnesemias are associated with Gitelman-like
electrolyte abnormalities [56], while others seem to affect
TAL function [57–59]. Physiologically, both have a high en-
ergy requirement, although the DCT seems to be a better can-
didate since it has the most mitochondria [60]. Still needing to
be clarified is which function of the mitochondrion is most
important in Mg2+ homeostasis: is it the ATP that is necessary
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to drive the Na+-K+-ATPase and to activate CNNM2 [61]? Or
could its role in Ca2+-signaling be key here?
MT-TI, SARS2, POLG1 and mitochondrial
deletions/duplications
Impaired mitochondrial function might be associated with hy-
pomagnesemia much more frequently than is currently real-
ized. At least three distinct mitochondrial syndromes are ac-
companied by hypomagnesemia: (1) deletions in the mito-
chondrial genome as seen in Kearns–Sayre syndrome [62]
(2) recessive mutations in the human gene SARS2 [57] and
(3) mutations in the mitochondrial tRNAIle gene MT-TI caus-
ing a syndrome with hypertension, hypercholesterolemia and
hypomagnesemia [56]. An additional two cases of patients
with hypomagnesemia and other mitochondrial diseases have
also been identified (mutations in POLG1 and the mitochon-
drial Pearson’s syndrome [63, 64]). Since checking serum
Mg2+ concentrations is not regular clinical practice, it would
be interesting to investigate the genuine frequency of hypo-
magnesemia in patients with mitochondrial disease.
Other hypomagnesemias
The remaining disorders associated with hypomagnesemia are
classified in this review as Bother hypomagnesemias’^ due to
their heterogenic nature. One of these is caused by mutations in
TRPM6, which encodes the DCT-specific apical Mg2+ trans-
porter TRPM6, resulting in an isolated hypomagnesemia (i.e.
no other symptoms except secondary to the hypomagnesemia).
Others, such as mutations in EGF and EGFR affect the activity
and expression of this channel [6]. FAM111A is the only gene in
this group of which the pathophysiological mechanism under-
lying the hypomagnesemia has received no attention at all.
TRPM6 (hypomagnesemia with secondary hypocalcemia)
Mutations in the gene for the DCT- and colon-specific apical
Mg2+ channel, TRPM6, cause the most profound genetic hy-
pomagnesemia [65, 66]. A measured serum Mg2+ concentra-
tion as low as 0.2 mM or even lower, as low as immeasurable
levels, is not uncommon in these patients [14]. Consequently,
patients often present with seizures within the first months of
life [14]. A defect in the TRPM6 channel impairs epithelial
Mg2+ resorption in the colon and DCT, thereby inhibiting
uptake and stimulating wasting of Mg2+, causing significant
hypomagnesemia [67]. The secondary hypocalcemia often
observed is probably caused by inhibition of the parathyroid
gland by the hypomagnesemia, resulting in low levels of para-
thyroid hormone and eventually leading to hypocalcemia [68].
CNNM2 (hypomagnesemia with seizures and mental
retardation)
CNNM2 is most highly expressed in the TAL, DCT and brain
[69, 70], which explains the combination of hypomagnesemia
with additional neurological symptoms (anatomical abnor-
malities, seizures and intellectual disability) seen in patients
with dominant or sometimes recessive CNNM2 mutations
[71]. Although CNNM2 was first thought to be a basolateral
Mg2+ transporter itself, it is now thought to fulfill the role of
intracellular Mg2+ sensor by undergoing a conformational
change upon binding of Mg-ATP [61]. How this conforma-
tional change eventually leads to the observed decrease in
Mg2+ transport, however, remains unclear, as is the precise
basis of the neurological symptoms.
EGF and EGFR (isolated recessive hypomagnesemia)
One mutation in the epidermal growth factor gene (EGF) has
been associated with a recessive form of hypomagnesemia with
an additional neurological phenotype (including intellectual
disability) [72]. The only mutation identified to date interferes
with proper trafficking of pro-EGF, which is expressed in TAL
and DCT cells, resulting in a decreased peritubular concentra-
tion of autocrine EGF [72]. Subsequently, the signaling cascade
from the EGF receptor (EGFR) to the Akt-mediated activation
of Rac1 is turned off, resulting in a decrease of endomembrane
trafficking of TRPM6 to the apical surface and decreasedMg2+
transport [6]. The intellectual disability on the other hand re-
mains unexplained.
Since EGF mutations and cetuximab (an EGFR inhibitor)
both cause hypomagnesemia [73], it is not surprising that mu-
tations in EGFR have also been found to cause hypomagne-
semia. Only one patient has been diagnosed to date with loss-
of-function of the EGFR. This mutation resulted in severe
symptoms comparable to those observed with full EGFR
blockade, including skin rash, inflammation of the lungs and
bowel and hypomagnesemia [74].
KCNA1 (autosomal dominant hypomagnesemia)
Intriguingly, only one mutation (identified with linkage in a
large pedigree) in KCNA1 has been associated with hypomag-
nesemia [75], while all other KCNA1mutations known to date
cause episodic ataxia type 1 without hypomagnesemia
(reviewed in [76]). The KCNA1 gene encodes the voltage-
gated K+ channel Kv1.1 [75], which is abundantly expressed
in certain neurons as well as on the apical membrane of cells in
the DCT ([75] and reviewed in [77]). In neurons, the mutations
in KCNA1 impair normal repolarization of the membrane po-
tential, resulting in stress-triggered episodes of ataxia and
myokymia [77]. Following the same line of reasoning, one
might speculate that genetic defects in Kv1.1 might cause
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hypomagnesemia by depolarizing the apical DCT membrane
[78]. However, this theory does not explain why other KCNA1
mutations have not been reported to cause hypomagnesemia.
Also, how does a voltage-gated K+-channel like KCNA1,
which is closed and thus non-functional at normal apical mem-
brane potential, cause hypomagnesemia in the first place?
FAM111A
Mutations in FAM111A are associated with two distinct dom-
inant diseases: a perinatally lethal disorder called gracile bone
dysplasia (GLCEB) and Kenny–Caffey syndrome type 2
(KCS2) [79]. To date, only KCS2 has been associated with
hypomagnesemia [80–85]. Other symptoms of KCS2 include
severe proportionate short stature, radiological bone anoma-
lies, eye abnormalities and hypocalcemia owing to hypopara-
thyroidism (reviewed in [82]). FAM111A has been reported to
be a host-range restriction factor [86] and shown to be an
important component of the cell’s replication machinery near
DNA forks, consistent with its proposed role in cancer and cell
survival [87–89]. However, it is unclear how this function
would link to hypomagnesemia. Alternatively, it might be
speculated that its function is related to the function of
TBCE [90], the causative gene for the clinically closely related
Kenny–Caffey syndrome type 1 [91].
Treatment
Oral or intravenous Mg2+ supplementation is the only treat-
ment available for hypomagnesemia of genetic origin. In the
acute s i tuat ion of a (severely) symptomat ica l ly
hypomagnesemic patient, intravenous Mg2+ supplementation
can be very important. For adults, a dose of 8–12 g of MgSO4
(containing 0.8–1.2 g ofMg2+) in the first 24 h is recommend-
ed, followed by 4–6 g/day for 3 or 4 days [92]. For the non-
acute setting, oral Mg2+ supplementation of 3×120 mg/day is
more convenient while being sufficiently effective [93].
Parenteral and oral Mg2+ supplementation is therefore recom-
mended in many of the hypomagnesemias, including
Gitelman syndrome, Bartter syndrome, EAST syndrome and
those caused by TRPM6mutations [14, 31, 41]. The resulting
rise in serum Mg2+ concentration often alleviates symptoms,
such as seizures and secondary hypocalcemia, even though
normal Mg2+ values are rarely reached [14, 75]. Further cor-
rection of the hypomagnesemia is generally impeded by the
gastro-intestinal side effects frequently associated with oral
Mg2+ supplementation. Paradoxically, higher doses of oral
Mg2+ might even be detrimental because of the resulting di-
arrhea [31]. Also, attention should be given to the type of oral
Mg2+ supplementation given since some preparations have a
better bioavailability than others. For this reason, we recom-
mend magnesium chloride or magnesium glycerophospate
rather than magnesium oxide or magnesium sulfate for oral
Mg2+ supplementation [31].
Since hypokalemia is commonly associated with hypo-
magnesemia, especially in the Gitelman-like hypomagnese-
mias, one might consider treatment with the epithelial Na+
channel ENaC or aldosterone blockers. However, care should
be taken, especially in the young child, since this treatment
will interfere with the distal compensatory salt reabsorption of
the kidney [27]. Lastly, seizures are a known result of several
Fig. 2 Diagnostic flowchart for a suspected genetic cause of
hypomagnesemia. This diagnostic flowchart is primarily provided to
give an impression of the clinical characteristics of all known genetic
causes of hypomagnesemia. Genetic testing can confirm or reject a
diagnosis. Asterisks indicate dominantly inherited disorders
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genetic hypomagnesemias, as a primary effect of the genetic
defect or secondary to the Mg2+ deficiency. In both cases,
treatment with anticonvulsants such as valproate or phenobar-
bital might be beneficial [41].
Summary and future perspectives
In summary, the identification of the different genetic hypo-
magnesemias has aided our understanding of the important
role of the kidney—the TAL and DCT in particular—in main-
taining Mg2+ homeostasis. Based on the combination of in-
creased fractional renal Mg2+ excretion with familial occur-
rence and a variety of additional symptoms, it is possible to
recognize cases with a genetic cause and differentiate between
them to a certain extent (see Fig. 2). Subsequent characteriza-
tion of the affected genes and proteins has improved our un-
derstanding of which molecular pathways are involved in
Mg2+ homeostasis. Hypercalciuric hypomagnesemia is there-
by often the presentation of a defect in the TAL, while
Gitelman-like and Bother^ hypomagnesemias are generally
localized to the DCT. Treatment still depends on Mg2+ sup-
plementation, but an increased understanding of the patho-
physiological mechanisms might make discovery of new
treatment opportunities possible in the future.
Additional fundamental research might further elucidate
the mechanisms of transport and regulation exploited by the
DCT and TAL to maintain Mg2+ homeostasis. Not only does
the basolateral Mg2+ transporter need to be identified, but the
precise pathophysiological mechanisms by which known mu-
tations cause hypomagnesemia also need further clarification.
This even holds true for several well-known and thoroughly
described hypomagnesemias, such as Gitelman syndrome.
After all, some observations cannot be explained by current
understanding. The proposed atrophy of the DCT, for exam-
ple, has been observed in mice with Gitelman syndrome [29],
but it is not present in mice on chronic thiazide treatment-
induced hypomagnesemia [30]. The proposed decisive role
for the membrane potential of the apical membrane is also
not completely satisfying, especially since its role is proven
for only some of the genetic hypomagnesemias [78].
On the other hand, some pathways linked to hypomagne-
semia might be underestimated. The EGF/EGFR pathway and
the insulin and estrogen pathways seem to be of significant
importance in terms of increasing Mg2+ transport but there is
currently little evidence linking them to hypomagnesemic pa-
thology (reviewed in [1]). Additionally, the role of the Na+-
K+-ATPase might be more important than currently appreci-
ated. The Na+-K+-ATPase is known to occupy a central posi-
tion in many of the Gitelman-like hypomagnesemia, while it
has the potential of being involved in EGFR activation by
means of the Na+-K+-ATPase-Src-kinase complex [94]. The
pathophysiology underlying mitochondria-associated
diseases might also be of great interest since at least one of
the other hypomagnesemias has been reported to be charac-
terized by a vastly diminished size and number of mitochon-
dria in the DCTcells [95]. However, it is not yet clear whether
this is a cause, epiphenomenon or result of the hypomagnese-
mia. Lastly, the recent breakthroughs in identifying new path-
ways involved in Na+ regulation by the DCT [96] could also
shed new light on the transport of other ions in this segment.
Identification of these other pathways will hopefully provide
decisive evidence on the mechanisms of Mg2+ reabsorption in
the kidney and might open new roads to causal treatment of
hypomagnesemia.
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